Bacteriologist Elizabeth Harry revolutionised her field by working out a better way to watch bacteria do their thing. And what she found was more than she ever expected.

Living Cell Technologies opens pig breeding facility ahead of xenotransplantation trials to treat type 1 diabetes.

New model aims to streamline medical device development and aid in gaining regulatory approval.

Clinical and research cytogeneticists are still using technology predominantly developed in the 1970s for their work, so the emergence of microarrays specifically for cytogenetics is coming as a welcome relief.

Australian researchers find that interfering RNA delivered via bacterially-derived minicells can target and kill drug resistant tumours.

Adult muscle stem cells rather than embryonic stem cells could be the key to treating muscular disorders.

Anti-anxiety drug, BNC210, to undergo phase I clinical trial in Adelaide.

Calls for Australian Government to lift moratorium on xenotransplantation so similar trials can occur here.

Hormone adiponectin could be used to better diagnose and treat type 2 diabetes.

CSL to evaluate Phosphagenics' TMP technology with the possibility of an expanded collaboration in the future.

Screening process completed for phase II clinical trial of interferon to treat influenza.

Scientists sequence genome of the N2-fixing, soil-living bacterium Azotobacter vinelandii.

European Medicines Agency grants Clinuvel new orphan drug designation for afamelanotide.

Two young researchers at Children’s Cancer Institute Australia for Medical Research (CCIA), Dr Joshua McCarroll and Dr Marcia Munoz, were today awarded significant funding from the Balnaves Foundation to further their promising research into childhood cancer.